Loading clinical trials...
Loading clinical trials...
A Comparison of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5mg, 1 Inhalation Two Times a Day (b.i.d.) Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults a -26-week, Randomized, Open-label, Parallel-group, Multicentre Study
Conditions
Interventions
Symbicort TBH - Turbuhaler
beta-II-agonist, inhale steroid
Locations
15
Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Antalya, Turkey (Türkiye)
Research Site
Bursa, Turkey (Türkiye)
Research Site
Denizli, Turkey (Türkiye)
Research Site
Diyarbakır, Turkey (Türkiye)
Research Site
Edirne, Turkey (Türkiye)
Start Date
December 1, 2005
Primary Completion Date
September 1, 2008
Completion Date
September 1, 2008
Last Updated
August 14, 2012
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions